GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Shiller PE Ratio

Sunesis Pharmaceuticals (FRA:RYIS) Shiller PE Ratio : (As of May. 25, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sunesis Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Sunesis Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Shiller PE Ratio Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sunesis Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Shiller PE Ratio falls into.



Sunesis Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sunesis Pharmaceuticals's E10 for the quarter that ended in Dec. 2020 is calculated as:

For example, Sunesis Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2020 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=-0.604/109.8968*109.8968
=-0.604

Current CPI (Dec. 2020) = 109.8968.

Sunesis Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201103 20.962 94.283 24.433
201106 -91.816 95.235 -105.952
201109 -58.778 95.727 -67.479
201112 -100.548 95.213 -116.054
201203 -166.919 96.783 -189.536
201206 -117.159 96.819 -132.984
201209 -211.033 97.633 -237.541
201212 -33.604 96.871 -38.123
201303 -130.507 98.209 -146.038
201306 -100.283 98.518 -111.866
201309 -87.965 98.790 -97.855
201312 -69.751 98.326 -77.959
201403 -138.165 99.695 -152.304
201406 -108.192 100.560 -118.238
201409 -142.590 100.428 -156.034
201412 -11.922 99.070 -13.225
201503 -88.288 99.621 -97.395
201506 -98.233 100.684 -107.222
201509 -61.123 100.392 -66.910
201512 -101.210 99.792 -111.458
201603 -77.004 100.470 -84.229
201606 -78.498 101.688 -84.835
201609 -67.672 101.861 -73.011
201612 -51.097 101.863 -55.127
201703 -53.833 102.862 -57.515
201706 -44.700 103.349 -47.532
201709 -44.194 104.136 -46.639
201712 -21.738 104.011 -22.968
201803 -20.863 105.290 -21.776
201806 -20.972 106.317 -21.678
201809 -18.897 106.507 -19.498
201812 -17.228 105.998 -17.862
201903 -10.841 107.251 -11.108
201906 -9.757 108.070 -9.922
201909 -6.340 108.329 -6.432
201912 -1.575 108.420 -1.596
202003 -5.543 108.902 -5.594
202006 -6.527 108.767 -6.595
202009 -3.016 109.815 -3.018
202012 -0.604 109.897 -0.604

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sunesis Pharmaceuticals  (FRA:RYIS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sunesis Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines